Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $13,540 | $11,878 | $90,827 | $120,930 |
| - Cash | $76,732 | $130,191 | $232,545 | $138,483 |
| + Debt | $19,668 | $33,582 | $13,977 | $693 |
| Enterprise Value | -$43,524 | -$84,731 | -$127,742 | -$16,860 |
| Revenue | $412 | $3,652 | $0 | $10,938 |
| % Growth | -88.7% | – | -100% | – |
| Gross Profit | $371 | -$4,739 | -$2,621 | $9,564 |
| % Margin | 90% | -129.8% | – | 87.4% |
| EBITDA | -$66,045 | -$101,411 | -$189,415 | -$89,756 |
| % Margin | -16,030.3% | -2,776.9% | – | -820.6% |
| Net Income | -$62,007 | -$113,012 | -$190,458 | -$91,076 |
| % Margin | -15,050.2% | -3,094.5% | – | -832.7% |
| EPS Diluted | -34.12 | -63.65 | -126.13 | -314.06 |
| % Growth | 46.4% | 49.5% | 59.8% | – |
| Operating Cash Flow | -$53,240 | -$100,136 | -$171,384 | -$87,024 |
| Capital Expenditures | -$486 | -$1,615 | -$2,866 | -$8,201 |
| Free Cash Flow | -$53,726 | -$101,751 | -$174,250 | -$95,225 |